NYSE:RDY Dr. Reddy's Laboratories (RDY) Stock Price, News & Analysis $81.22 +0.38 (+0.47%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$81.16▼$81.9850-Day Range$68.25▼$80.9052-Week Range$63.72▼$81.98Volume250,253 shsAverage Volume226,175 shsMarket Capitalization$13.55 billionP/E Ratio20.15Dividend Yield0.50%Price Target$81.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Dr. Reddy's Laboratories alerts: Email Address Dr. Reddy's Laboratories MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside0.3% Downside$81.00 Price TargetShort InterestHealthy1.16% of Shares Sold ShortDividend StrengthWeakBased on Four FactorsSustainabilityN/ANews Sentiment0.01Based on 20 Articles This WeekInsider TradingN/AProj. Earnings Growth-4.22%From $4.03 to $3.86 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.59 out of 5 starsMedical Sector884th out of 936 stocksPharmaceutical Preparations Industry416th out of 436 stocks 1.0 Analyst's Opinion Consensus RatingDr. Reddy's Laboratories has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageDr. Reddy's Laboratories has only been the subject of 1 research reports in the past 90 days.Read more about Dr. Reddy's Laboratories' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.16% of the outstanding shares of Dr. Reddy's Laboratories have been sold short.Short Interest Ratio / Days to CoverDr. Reddy's Laboratories has a short interest ratio ("days to cover") of 7.3.Change versus previous monthShort interest in Dr. Reddy's Laboratories has recently decreased by 2.51%, indicating that investor sentiment is improving. Previous Next 1.7 Dividend Strength Dividend YieldDr. Reddy's Laboratories has a dividend yield of 0.51%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthDr. Reddy's Laboratories does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Dr. Reddy's Laboratories is 10.17%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Dr. Reddy's Laboratories will have a dividend payout ratio of 10.62% next year. This indicates that Dr. Reddy's Laboratories will be able to sustain or increase its dividend.Read more about Dr. Reddy's Laboratories' dividend. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RDY. Previous Next 2.2 News and Social Media Coverage News SentimentDr. Reddy's Laboratories has a news sentiment score of 0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Dr. Reddy's Laboratories this week, compared to 3 articles on an average week.Search Interest3 people have searched for RDY on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Dr. Reddy's Laboratories to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Dr. Reddy's Laboratories insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.00% of the stock of Dr. Reddy's Laboratories is held by insiders.Percentage Held by InstitutionsOnly 14.02% of the stock of Dr. Reddy's Laboratories is held by institutions.Read more about Dr. Reddy's Laboratories' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Dr. Reddy's Laboratories are expected to decrease by -4.22% in the coming year, from $4.03 to $3.86 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dr. Reddy's Laboratories is 20.15, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 143.45.Price to Earnings Ratio vs. SectorThe P/E ratio of Dr. Reddy's Laboratories is 20.15, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 164.48.Price to Earnings Growth RatioDr. Reddy's Laboratories has a PEG Ratio of 1.80. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioDr. Reddy's Laboratories has a P/B Ratio of 4.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressNew trading system called MSFT, NVDA & MSFTLook 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.Just follow this link here! About Dr. Reddy's Laboratories Stock (NYSE:RDY)Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.Read More RDY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RDY Stock News HeadlinesJuly 10, 2024 | marketbeat.comTeva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem (RDY)Drug prices continue to rise, driving up healthcare costs. Pharmaceutical companies usually hike drug prices at the beginning of each year. In January 2024July 26 at 7:50 PM | markets.businessinsider.comDr Reddys Laboratories earnings: here's what Wall Street expectsJuly 26, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.July 26 at 3:44 AM | americanbankingnews.comZacks Research Equities Analysts Cut Earnings Estimates for Dr. Reddy's Laboratories Limited (NYSE:RDY)July 25 at 9:20 AM | americanbankingnews.comDr. Reddy's Laboratories Limited (NYSE:RDY) to Issue $0.41 Annual DividendJuly 23 at 8:12 AM | marketwatch.comDr. Reddy's Laboratories rises Tuesday, outperforms marketJuly 21, 2024 | finance.yahoo.comRDY Aug 2024 80.000 put (RDY240816P00080000)July 21, 2024 | finance.yahoo.comRDY Aug 2024 85.000 call (RDY240816C00085000)July 26, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.July 21, 2024 | ca.finance.yahoo.comRDY Sep 2024 55.000 putJuly 21, 2024 | ca.finance.yahoo.comRDY Dec 2024 100.000 callJuly 19, 2024 | marketwatch.comDr. Reddy's Laboratories rises Thursday, still underperforms marketJune 26, 2024 | businesswire.comDr. Reddy's to Acquire Nicotinell and Related Portfolio in Significant Step Towards Building Global Consumer Healthcare BusinessJune 3, 2024 | businesswire.comAurigene Pharmaceutical Services Limited, a Global CRDMO, Announces the Opening of Its Biologics Facility Offering Process Development and Clinical Scale Manufacturing CapabilitiesMay 28, 2024 | businesswire.comDr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North AmericaMay 21, 2024 | businesswire.comAlvotech and Dr. Reddy's Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UKMay 21, 2024 | finance.yahoo.comAlvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UKMay 8, 2024 | finance.yahoo.comDr. Reddy’s Laboratories Limited (NYSE:RDY) Q4 2024 Earnings Call TranscriptSee More Headlines Receive RDY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dr. Reddy's Laboratories and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today7/26/2024Ex-Dividend for 7/30 Dividend7/30/2024Dividend Payable7/30/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:RDY CUSIPN/A CIK1135951 Webwww.drreddys.com Phone914049002900Fax91-40-4900-2999Employees27,048Year Founded1984Price Target and Rating Average Stock Price Target$81.00 High Stock Price Target$81.00 Low Stock Price Target$81.00 Potential Upside/Downside-0.7%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)$4.03 Trailing P/E Ratio20.23 Forward P/E Ratio20.23 P/E Growth1.8Net Income$668 million Net Margins19.97% Pretax Margin25.73% Return on Equity21.32% Return on Assets15.47% Debt Debt-to-Equity Ratio0.02 Current Ratio2.58 Quick Ratio1.92 Sales & Book Value Annual Sales$3.35 billion Price / Sales4.06 Cash Flow$5.16 per share Price / Cash Flow15.79 Book Value$20.17 per share Price / Book4.04Miscellaneous Outstanding Shares166,890,000Free Float163,555,000Market Cap$13.61 billion OptionableOptionable Beta0.56 Social Links 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Gunupati Venkateswara Prasad B.E. (Age 64)Co-Chairman, MD & Member of Management Council Comp: $2.25MMr. Kallam Satish Reddy B.Tech. (Age 57)M.S., Chairman of the Board & Member of the Management Council Comp: $1.38MMr. Erez Israeli M.B.A. (Age 56)CEO & Member of the Management Council Mr. Parag Agarwal (Age 57)CFO & Member of Management Council Mr. Deepak Sapra M.B.A. (Age 49)CEO of API & Services & Member of Management Council Mr. Venkata Ramana Motupalli M.B.A. (Age 55)CEO of Branded Markets - India & Emerging Countries and Member of Management Council Ms. Archana Bhaskar B.Sc. (Age 57)M.B.A., EVP, Head of Corporate Communications, Chief Human Resources Officer & Member of Management Council Mr. Sanjay Sharma B.Tech. (Age 56)Executive VP, Global Head of Global Manufacturing & Member of Management Council Mr. Marc Kikuchi B.A. (Age 55)M.B.A., CEO of North America Generics & Member of Management Council Mr. Patrick Aghanian B.A. (Age 59)M.B.A., CEO of European Generics & Member of Management Council More ExecutivesKey CompetitorsModernaNASDAQ:MRNATakeda PharmaceuticalNYSE:TAKTeva Pharmaceutical IndustriesNYSE:TEVABeiGeneNASDAQ:BGNECatalentNYSE:CTLTView All CompetitorsInstitutional OwnershipAllspring Global Investments Holdings LLCSold 19,238 shares on 7/26/2024Ownership: 0.053%Bank of New York Mellon CorpBought 489 shares on 7/26/2024Ownership: 0.016%Summit Global InvestmentsBought 1,081 shares on 7/22/2024Ownership: 0.018%Legacy Capital Group California Inc.Bought 2,672 shares on 7/22/2024Ownership: 0.002%Lifestyle Asset Management Inc.Sold 1,152 shares on 7/19/2024Ownership: 0.008%View All Institutional Transactions RDY Stock Analysis - Frequently Asked Questions How have RDY shares performed this year? Dr. Reddy's Laboratories' stock was trading at $69.58 at the beginning of the year. Since then, RDY shares have increased by 16.7% and is now trading at $81.22. View the best growth stocks for 2024 here. How were Dr. Reddy's Laboratories' earnings last quarter? Dr. Reddy's Laboratories Limited (NYSE:RDY) released its quarterly earnings results on Tuesday, May, 7th. The company reported $0.94 earnings per share for the quarter, beating analysts' consensus estimates of $0.86 by $0.08. The firm earned $850 million during the quarter, compared to analysts' expectations of $825.20 million. Dr. Reddy's Laboratories had a net margin of 19.97% and a trailing twelve-month return on equity of 21.32%. What is G. V. Prasad's approval rating as Dr. Reddy's Laboratories' CEO? 528 employees have rated Dr. Reddy's Laboratories Chief Executive Officer G. V. Prasad on Glassdoor.com. G. V. Prasad has an approval rating of 96% among the company's employees. This puts G. V. Prasad in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. Who are Dr. Reddy's Laboratories' major shareholders? Dr. Reddy's Laboratories' top institutional investors include Allspring Global Investments Holdings LLC (0.05%), Assenagon Asset Management S.A. (0.04%), Summit Global Investments (0.02%) and Bank of New York Mellon Corp (0.02%). How do I buy shares of Dr. Reddy's Laboratories? Shares of RDY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Dr. Reddy's Laboratories own? Based on aggregate information from My MarketBeat watchlists, some other companies that Dr. Reddy's Laboratories investors own include Siemens Aktiengesellschaft (SIEGY), Tata Motors (TTM), Infosys (INFY), HDFC Bank (HDB), Alibaba Group (BABA) and GSK (GSK). This page (NYSE:RDY) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dr. Reddy's Laboratories Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Dr. Reddy's Laboratories With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RDY Stock Alerts